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Endochondral bone formation is orchestrated by mesenchymal cell condensation to form cartilage anlagen, which act as a template for bone
formation and eventual mineralization. The current study performed gene expression analysis to examine pre- and post-mineralization stages (E15
and E19) of endochondral bone formation, using fetal metatarsal long bones as a model. An extensive number of genes were differentially
expressed, with 543 transcripts found to have at least 2-fold up-regulation and 742 with a greater than 2-fold down-regulation. A bioinformatics
approach was adopted based on gene ontology groups, and this identified genes associated with the regulation of signaling and skeletal
development, cartilage replacement by bone, and matrix degradation and turnover. Transcripts linked to skeletal patterning, including Hoxd genes
10–12, Gli2 and Noggin were considerably down-regulated at E19. Whereas genes associated with bone matrix formation and turnover, ACP5,
MMP-13, bone sialoprotein, osteopontin, dentin matrix protein-1 and MMP-9 all were distinctly up-regulated at this later time point. This
approach to studying the formation of the primary ossification center provides a unique picture of the developmental dynamics involved in the
molecular and biochemical processes during this intricately regulated process.
© 2006 Elsevier B.V. All rights reserved.Keywords: Microarray; Endochondral bone; Remodeling; Gene expression1. Introduction
The formation of bone is a complex and highly regulated
process, occurring through two distinct mechanisms, intramem-
branous and endochondral ossification. Intramembranous
ossification occurs in a few skeletal elements such as the lateral
halves of the clavicles and parts of the skull. These form from
the direct condensation of mesenchymal cells to osteoblasts,
which secrete a bone matrix that becomes mineralized [1].
However, the axial and appendicular skeleton is formed by
endochondral ossification, through processes that are initiated
during embryogenesis when mesenchymal cells form focal
condensations and differentiate into chondrocytes [2]. In the
growth plate, proliferating chondrocytes secrete an extracellular⁎ Corresponding author. Centre for Oral Biology, Karolinska Institutet P.O.
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doi:10.1016/j.bbamcr.2006.08.027matrix (ECM), rich in type II collagen and the proteoglycan
(PG), aggrecan, which results in the formation of avascular
anlagen. With growth, chondrocytes become hypertrophic and
synthesize type X collagen, and eventually such cartilage
becomes calcified. The hypertrophic chondrocytes attract blood
vessels through the production of vascular endothelial growth
factor (VEGF) and other angiogenic factors, and furthermore,
they recruit perichondral cells to become osteoprogenitors, prior
to their apoptosis. Osteoblasts, together with the vasculature
invade the anlagen left by the chondrocytes, and the secreted
ECM mineralizes to form new trabecular bone. The process
gradually proceeds in the longitudinal direction and results in
two defined structures known as growth plates, one at the
primary ossification site, diaphysis, and one at the secondary
site of ossification, epiphysis.
Endochondral ossification is a dynamic process, with well-
characterized stages of development. Previous studies have
extensively characterized the tissues using histological and
morphological approaches and a vast array of molecules have
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the growth plate, osteoblast recruitment, osteoclast activity and
bone remodeling (for review see [2–6]). Of particular interest
are those proteins involved in the initiation and regulation of
osteodifferentiation and/or the mineralization processes, some
examples including the transcription factors, Runx2 [7,8] and
osterix (OSX) [9], and ECM proteins such as bone sialoprotein
(BSP) and osteocalcin (OCN) [10–12]. Remodeling of the
cartilage matrix and bone turnover is instigated by proteolytic
breakdown and an extensive number of proteases have been
implicated, including the family of matrix metalloproteinases
(MMP) and the bone resorbing enzyme tartrate resistant acid
phosphatase (TRAP) [6,13].
However, how these molecules form a dynamic molecular
network to regulate the process of early osteogenesis remains to
be fully appreciated. Large scale gene array analysis offers the
possibility to define the global gene expression pattern within
cell populations or tissues. Two previous investigations have
used such an approach of gene expression analysis to study
endochondral bone formation. Clancy et al. [14] showed that
bone matrix protein 2 (BMP2) could induce endochondral
ossification in mouse quadriceps. Genes were identified that had
previously been associated with bone and cartilage metabolism,
such as aggrecan, Runx2 and procollagen types II and X,
whereas the study by Wang et al. [15] isolated chondrocytes
from the proliferative and hypertrophic growth plate zones from
long bones of adult rats. The current study was designed to
further define the dynamic changes in the molecular and
biochemical processes that occur during the formation of the
primary ossification center. Thus, mouse metatarsals from
embryonic stages 15 and 19, representing pre- and post-bone
mineralization phases, were subjected to gene expression
analysis, in order to examine the changes which occurred
during the development and initial mineralization of endochon-
dral bones.
2. Materials and methods
2.1. Tissue preparation and RNA isolation
Central mouse metatarsals of the NMR1 strain (Scanbur. BK AB,
Stockholm, Sweden) were dissected free under sterile conditions on embryonic
days 15 (76 bones) and 19 (64 bones). The long bones were washed twice in
phosphate buffered saline (PBS) and total RNAwas extracted using the TRIzol
reagent (Invitrogen Carlsbad, CA, USA), according to the manufacturer's
instructions. The purified total RNA was resuspended in 30 μl RNAase-free
water. The RNA quality was determined by calculating the OD 260/280 ratio via
spectroscopy and its integrity was confirmed on an ethidium bromide-containing
1% agarose/formaldehyde gel. The Aligent 2100 Bioanalyser (Aligent
Technologies, Inc., Pal Alto, CA, USA) was also used to examine the integrity
(>1 μg/μl) of the RNA. The dissection and RNA isolation was repeated on a
separate occasion, to provide replicate analyses (n=2).
2.2. Microarray gene expression analysis
Expression profiling was performed for each RNA sample (E15 n=2, E19
n=2) separately on the GeneChip® Mouse Genome 430 2.0 Array (Affymetrix,
Inc., Santa Clara, CA, USA). This array contained approximately 34,000 well-
characterized mouse genes and details of the probe set can be obtained at http://
affymetrix.com/products/arrays/index.affx.The analysis, including RNA processing, labeling and hybridization to the
GeneChips®, was performed at the Bioinformatics and Expression Analysis
core facility at NOVUM, Karolinska Institutet, Sweden. All reagents and
protocols followed those described in the Affymetrix manuals. Initially, mRNA
was reverse transcribed from the total RNA (5 μg) using the T7-Oligo (dT)
Promoter Primer in the first strand cDNA synthesis. After second strand
synthesis, in the presence of RNAase H, the double-stranded cDNA template
was used for in vitro transcription, in the presence of T7 RNA polymerase and
the biotinylated nucleotide analog/ribonucleotide mix (UTP and CTP) to
produce labeled cRNA. The labeled RNAwas fragmented and hybridized to the
Mouse Genome 430 2.0 Array for 16 h at 45 °C with rotation. After hybrid-
ization, the arrays were washed and stained with streptavidin–phycoerythrin
(Molecular Probes Inc, Eugene, OR, USA), in a GeneChip® Fluidics Station
450 (Affymetrix), according to the recommendations of the manufacturer. The
GeneChip® arrays were then scanned using the Affymetrix Scanner 3000, in
preparation for analysis.
2.3. Data analysis and statistics
The expression values for each gene were calculated using the GeneChip®
Operating System (GCOS, Affymetrix). In order to minimize inconsistencies
due to variations, such as hybridization conditions, staining or probe array lot, all
probe sets were scaled from each array to a target intensity value of 100, to allow
for inter-array comparisons.
The GCOS software was used to derive a list of those genes that were
differentially expressed between E15 and E19. This list was then used within the
GeneSifter® software (VizXLabs, Seattle, USA), to determine fold changes
between E15 and E19, and to classify genes according to the standardized gene
ontology groups (GO (Gene Ontology Consortium, www.geneontology.org)):
Biological Process, Cellular Component and Molecular Functions. Within
GeneSifter®, a pairwise analysis was performed using Bonferroni correction; all
the genes were subjected to a filter of 2-fold change in gene expression, and a
detection P value of <0.005 was deemed to be significant.
2.4. cDNA synthesis and semi-quantitative reverse transcriptase
polymerase chain reaction (Sq-RT-PCR)
Single-stranded cDNAwas synthesized for use in Sq-RT-PCR from the total
RNA isolated from E15 and E19 mouse metatarsals. Five micrograms of total
RNAwas incubated with 50 μMOligo (dT)20(Invitrogen) and 10 mM dNTPmix
(Roche Diagnostics Scandinavia AB, Stockholm, Sweden) at 65 °C for 5 min,
then immediately placed onto ice for 1 min. The denatured RNA was reverse
transcribed with 5× first-strand buffer (Invitrogen), 0.1MDTT (Invitrogen), 1 μl
RNAase inhibitor (Roche Diagnostics Scandinavia AB) and 200 U/μl
SuperScript III RT (Invitrogen) at 50 °C for 45 min. The reaction was termi-
nated by heating to 70 °C for 15 min.
Analysis of the microarray data identified a number of interesting genes that
warranted further investigation by Sq-RT-PCR. These genes and corresponding
primer sequences are detailed in Table 1. The PCR reaction used 1 μg of cDNA
with the PCR Core Kit (Roche Diagnostics Scandinavia AB). A typical reaction
used the following conditions; 94 °C for 2 min; then 94 °C, 45 s; 53 °C (all
primer pairs except MMP 13, 48 °C), 45 s; 72 °C, 1 min repeated for 30 cycles
and 72 °C for 5 min. The Sq-RT-PCR products were visualized on a 2% agarose
gel containing ethidium bromide and photographed.
2.5. Histological staining
For histological analyses, entire mouse paws from E15 and E19, were fixed
in 4% paraformaldehyde for 3 h at 4 °C. The samples were then decalcified in
12.5% (w/v) ethylenediaminetetraacetic acid (EDTA) solution, pH 7.0 for
2 days, dehydrated and embedded in paraffin. Seven-micrometer thin sections
were mounted on Super Frost Plus glass slides (Menzel-Gläser, Braunschweig,
Germany). The sections were dipped in xylene to remove the paraffin and
rehydrated through a series of graded alcohols and then rinsed in Tris buffered
saline. The sections were stained with Masson's Trichrome, and to identify pre-
osteoclasts and osteoclasts sections were stained for tartrate-resistant acid
phosphatase (TRAP) with fast red violet 1b salt as described [16].
Table 1
Primer pairs used in template synthesis for Sq-RT-PCR analysis
Gene
symbol
GeneBank
ID
Sequences (5′–3′) Product
size (bp)
GAPDH NM_008084 Forward:
CAATGTGTCCGTCGTGGATCT
163
Reverse:
CGTGCCGCCTGGAGAAACCTGCC
OSX/SP 7 NM_130458 Forward:
ACTCATCCCTATGGCTCGTGGTA
155
Reverse:
AGGCAGGCATCCACGCAGGCATCT
ACP5 AK008391 Forward:
AAGAACTTGCGACCATTGTTAGC
244
Reverse:
AGCCGCCCAGGGAGTCCTCAGATC
IBSP NM_008318 Forward:
TTTCAGCAGACAACCCCACC
189
Reverse:
AGCCTATGGGACCACCTCGCCACC
OSAD NM_012050 Forward:
ATGGTGTATTCGCTAAACTTTCAA
194
Reverse:
AGTCACATTCACCAGCCCGTCCAT
CHAD NM_007689 Forward:
CCACAACGACATCCGGGTATT
152
Reverse:
AGCTGGAGCCTTCGACGACCTGAC
DMP 1 U65020 Forward:
CAGCAAAGACCAGGACAGTGA
162
Reverse:
CGAACTCAGAACCGTCCCCGTGGC
SPOCK 3 NM_023689 Forward:
CCGTCATCTACCTGCAAGCC
172
Reverse:
TGCCCTATCGCCTATGCCAGCCCA
MMP 9 NM_013599 Forward:
CGTGATCCCCACTTACTATGGAA
150
Reverse:
TACACCAAGGCGTGCCGTCGTTGC
MMP 13 NM_008607 Forward:
CCTTCTTCTTGTTGAGCTGGACT
173
Reverse:
CCTGTTGGTCCCTGCCCCTTCCCT
TIMP 1 BC008107 Forward:
TACACCCCAGTCATGGAAAGC
192
Reverse:
ATGCCCACAAGTCCCAGAACCGC
CTS K NM_007802 Forward:
CGGAATAAGAACAACGCCTGC
199
Reverse:
CATCGCTGCGTCCCTCTCAGGAGC
NOG NM_008711 Forward:
TGTGGTCACAGACCTTCTGC
156
Reverse:
GTGAGGTGCACAGACTTGGA
BMP 2 NM_007553 Forward:
GCTCCACAAACGAGAAAAGC
177
Reverse:
AGCAAGGGGAAAAGGACACT
GAPDH—glyceraldehyde-3-phosphate dehydrogenase, OSX/SP 7—osterix,
ACP5—acid phosphatase 5, IBSP—integrin bone sialoprotein, OSAD—
osteoadherin, CHAD—chondroadherin, DMP 1—dentine matrix protein 1,
SPOCK 3—SPARC/ON, CWCV and Kaza—like domain proteoglycan 3,
MMP 9—matrix metalloproteinase 9 , MMP 13—matrix metalloproteinase 13,
TIMP 1—tissue inhibitor of matrix metalloproteinases 1, CTS K—cathepsin K,
Nog—noggin, BMP 2—bone morphogenic protein 2, bp—base pair.
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Skeletal long bone development is a tightly controlled
process, involving the careful balance of a distinct number of
pathways: from skeletal morphogenesis, including patterning
and condensation, to overt organogenesis of chondrocyte
differentiation, apoptosis and cartilage matrix remodeling, and
eventual vascular invasion and trabecular bone formation.
Throughout these sequential and overlapping phases, an
extensive number of factors interplay, with each step dependent
upon the previous one, and each subject to different genetic
control. This investigation has used microarray analysis to
assess the gene expression pattern between two chosen
developmental stages of embryonic endochondral ossification,
in an attempt to characterize the dynamic changes in global gene
expression patterns during this intricately regulated event.
Embryonic stage E15 (Fig. 1A), was characterized by a
metatarsal precursor, which consisted of an avascular cartilage
anlagen and pre-hypertrophic chondrocytes in the diaphysis.
The developing metatarsal was surrounded by a perichondrium
of dense mesenchymal cells. However, by E19, the cartilage
anlagen was constricted and surrounded by a perichondral collar
of new trabecular bone. The bone collar had invaded into the
cartilage matrix to form a primary marrow cavity (Fig 1B).
Masson's Trichrome staining showed collagen fibers to be
stained blue, and TRAP activity was only detected at E19 (Fig.
1C and D), with intense staining in several large cells (stained
red, arrows) in the primary ossification center.
Gene expression analysis of the total RNA isolated from
mouse metatarsals embryonic stages E15 and E19 identified an
extensive number of genes to be differentially expressed.
However, following stringent data analysis, these were
condensed to 1285 genes, of which 543 were at least up-
regulated on E19 compared to E15, and 742 were down-
regulated, based on a selection criteria of 2-fold change and a
detection P value of <0.005 (refer to Materials and methods). A
bioinformatics approach was adopted to investigate the
functional meaning of the differences in gene expression,
employing the GO categories: Biological Process (Fig. 2 and
Table 2), Cellular Component (Fig. 3 and Table 3) andMolecular
Function. Further breakdown of these classifications within the
GO classes, followed a bias towards bone development and
mineralized tissues. The differential expression of genes from
several stages of ossification was identified, including regula-
tory signals and skeletal development, replacement of cartilage
by bone, and matrix degradation and turnover. However, it
should be noted that across the GO databases, many entries were
found in several classifications, due to the multi-functional roles
of these molecules.
Classification based on the Biological Process Ontology
identified 528 genes that were involved in physiological, and
152 genes linked to developmental processes. Fig. 2 shows the
breakdown of these two processes. The tree resulted in three
groups of genes that had particular relevance to hard tissue
formation: skeletal development (25 genes), ossification (11
genes) and regulation of bone remodeling (5 genes) (Table 2).
Two main classifications were apparent from the Cellular
Fig. 1. Histological examination of the mouse metatarsals at E15 and E19. (A, B) Massan's Trichrome stained metatarsals from E15 and E19 mice: collagen fibers are
stained blue. (C, D) Staining for TRAP identified the presence of osteoclasts (red stained cells showed by arrows) in the E19 metatarsals within the primary ossification
center.
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(Fig. 3). Due to the large number of genes identified, the
extracellular group was focused upon, and its breakdownFig. 2. Classification of the gene expression data based on the Biological Proce
physiological processes were broken down into skeletal development, ossification aresulted in the division of two further sub-classes, ECM (50
genes, listed in Table 3) and extracellular space (250 genes,
Supplemental Table 1). Within the Molecular Function GOss gene ontology group. The sub-divisions of developmental processes and
nd the regulation of bone remodeling associated genes respectively.
Table 2
Genes identified from the Biological Process gene ontology database associated with skeletal development (25 genes), ossification (*11 genes) and the regulation of
bone remodelling (‡ 5 genes)
Chip ID Name Gene symbol Gene ID Chromosome Fold-change ↑/↓
1417484_at Integrin binding sialoprotein (bone sialoprotein)* Ibsp (BSP) NM_008318 5 E5 312.1↑
1449254_at Secreted phosphosprotein 1 (osteopontin)* Spp1 (OPN) NM_009263 5 E5 190.2↑
1426005_at Dentine matrix protein 1* Dmp1 U65020 5 E5 64.6↑
1449880_s_at Bone gamma carboxyglutamate protein 1 (osteocalcin)* ‡ Bglap1 (OCN) NM_007541 3 F1 7.8↑
1418176_at Vitamin D receptor Vdr AV290079 15 F1 6.3↑
1450627_at Progressive ankylosis Ank NM_020332 15 B1 5.3↑
1449466_at C-type lectin domain family 3, member b Clec3b NM_011606 9 F1–F3 5.2↑
1421979_at Phosphate regulatory gene with homologies to endopeptidases
on the X chromosome*
Phex BM214765 X F4 4.4↑
1459546_s_at Ectonucleotide pyrophosphatase/phosphodiesterase Enpp1 C76301 10 A4 4.4↑
1420653_at Transforming growth factor, beta 1 Tgfb1 NM_011577 7 A3 3.8↑
1416953_at Connective tissue growth factor* Ctgf NM_010217 10 A3–B1 3.7↑
1416321_s_at Proline arginine-rich end leucine-rich repeat protein Prelp BC019775 1 E4 3.5↑
1448416_at Matrix gamma-carboxyglutamate (gla) protein* ‡ Mglap NM_008597 6 G1 2.7↑
1437419_at BMP2-inducible kinase* ‡ Bmp2k BB329439 5 E3 2.5↑
1417092_at Parathyroid hormone receptor 1 * ‡ Pthr1 BC013446 9 F 2.5↑
1450673_at Procollagen, type IX, alpha 2 Col9a2 NM_007741 4 D2 2.4↑
1448914_a_at Colony stimulating factor 1 (macrophage)* Csf1 BM233698 3 F3 2.4↑
1421073_a_at Prostaglandin E receptor 4 (subtype EP4)* ‡ Ptger4 NM_008965 15 A1 2.4↓
1422300_at Noggin Nog NM_008711 11 C 2.5↓
1459211_at GLI-Kruppel family member Gli2 AW546128 1 E2–E4 2.6↓
1423428_at Receptor tyrosine kinase-like orphan receptor 2 Ror2 AV324603 13 2.9↓
1425083_at Otoraplin Otor AF243504 2 G1 3.2↓
1418606_at Homeo Box D10 Hoxd10 BC013463 2 C3 4.4↓
1450584_at Homeo Box D11 Hoxd11 NM_008273 2 C3 4.6↓
1450553_at Homeo Box D12 Hoxd12 NM_008274 2 C3 6.9↓
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functions, 236 catalytic activity and 44 had structural molecule
functions. However, these functions were not studied exten-
sively and the study focused on the Biological Process and
Cellular Component Ontology data.
The gene expression data followed the anticipated scheme of
development, in that an extensive number of factors known to
be involved in regulatory signaling and skeletal developmentFig. 3. Classification of the gene expression data based on the Cellular Componen
extracellular space and extracellular matrix.were considerably down-regulated post-mineralization (E19),
such as the Hoxd genes 10–12 (Homeobox D10 (4.4-fold), D11
(4.6-fold) and D12 (6.9-fold)) Gli2 (2.6-fold) and Noggin (2.5-
fold). The Hoxd genes 10–12 are transcription factors, and in
addition to an involvement in skeletal patterning [17], [18] and
defining anterior–posterior asymmetry patterning [19], have
been shown to influence the downstream regulation of factors
necessary for chondrocyte proliferation and differentiation [20],t gene ontology group and the sub-division of extracellular genes divided into
Table 3
Genes identified from the Cellular Component gene Ontology grouping associated with the extracellular matrix
Chip ID Name Gene symbol Gene ID Chromosome Fold-change↑/↓
1417256_at Matrix metalloproteinase 13 Mmp13 NM_008607 9 A1–A2 295.4 ↑
1426005_at Dentin matrix protein 1 Dmp1 U65020 5 E5 64.6↑
1422253_at Procollagen, type X, alpha 1 Col10a1 NM_009925 10 51.9↑
1448291_at Matrix metalloproteinase 9 Mmp9 NM_013599 2 H1–H2 36.0↑
1418454_at Microfibrillar associated protein 5 Mfap5 BC025131 6 F1 27.5↑
1450798_at Tenascin XB Tnxb NM_031176 17 B1 17.7↑
1428455_at Procollagen, type XIV, alpha 1 Col14a1 BB521934 15 D 12.2↑
1415939_at Fibromodulin Fmod NM_021355 1 E4 10.1↑
1420569_at Chondroadherin Chad NM_007689 11 D 8.3↑
1419703_at Procollagen, type V, alpha 3 Col5a3 NM_016919 9 A3 7.6↑
1418511_at Dermatopontin Dpt NM_019759 1 H2 7.2↑
1437889_x_at Biglycan Bgn AI931862 X F4 6.9↑
1416652_at Asporin Aspn AF316825 13 B1 5.7↑
1448613_at Extracellular matrix protein 1 Ecm1 NM_007899 3 F2 5.3↑
1449368_at Decorin Dcn NM_007833 10 C3 5.3↑
1449466_at C-type lectin domain family, member 3 Clec3b NM_011606 9 F1–F3 5.2↑
1421114_a_at Dermatan sulphate proteoglycan 3 Dspg3 NM_007884 10 C2–C3 4.9↑
1460227_at Tissue inhibitor of metalloproteinase 1 Timp1 BC008107 X A1 4.7↑
1416114_at SPARC-like 1 (mast9, hevin) Sparcl1 NM_010097 5 E4 3.9↑
1420653_at Transforming growth factor, beta 1 Tgfb1 NM_011577 7 A3 3.8↑
1416953_at Connective tissue growth factor Ctgf NM_010217 10 A3–B1 3.7↑
1416321_s_at Proline arginine-rich end leucine-rich repeat Prelp BC019775 1 E4 3.5↑
1420854_at Elastin Eln NM_007925 5 G2 3.2↑
1452250_a_at Procollagen, type VI, alpha 2 Col6a2 BI455189 10 B5 3.1↑
1421633_a_at Hyaluronan and proteoglycan link protein 1 Hapln1 NM_013500 13 C3 3.0↑
1423606_at Periostin osteoblast specific factor 2 Postn BI110565 3 C 3.0↑
1419442_at Matrilin 2 Matn2 BC005429 15 B3 2.9↑
1452284_at Protein tyrosine phosphatase, receptor type 2 polypeptide 1 Ptprz1 BC002298 6 A3.1 2.5↑
1417389_at Glypican 1 Gpc1 NM_016696 1 D 2.5↑
1423578_at Procollagen, type XI, alpha 2 Col11a2 AV242706 17 B1 2.5↑
1418670_s_at Perlecan (heparan sulfate proteoglycan 2) Hspg2 NM_008305 4 D3 2.4↑
1450673_at Procollagen, type IX, alpha 2 Col9a2 NM_007741 4 D2.2 2.4↑
1421172_at A disintegrin and metalloproteinase domain 12 (meltrin alpha) Adam12 BI964347 7 F3 2.4↑
1448392_at Secreted acidic cysteine rich glycoprotein Sparc NM_009242 11 B1 2.4↑
1418745_at Osteomodulin/osteoadherin Omd/Osad NM_012050 13 A5 2.3↑
1424131_at Procollagen, type VI, alpha 3 Col6a3 AF064749 1 D 2.2↑
1422518_at Calcium/calmodulin-dependent serine protein kinase Cask NM_009806 X A1 2.2↑
1448592_at Cartilage associated protein Crtap NM_019922 9 F3–F4 2.1↑
1427986_a_at Procollagen, type XVI, alpha 1 Col16a1 BB766878 4 D2 2.1↑
1456515_s_at Transcription factor-like 5 – AV044715 2 H4 2.0↑
1448870_at Latent transforming growth factor beta binding protein 1 Ltbp1 AF022889 17 E3 2.2↓
1422158_at Calsyntenin 2 Clstn2 NM_022319 9 E3 2.5↓
1421990_at Synaptotagmin 1 Syt1 NM_009306 10 D1 2.6↓
1419581_at Discs, large homolog 4 (Drosophila) Dlgh4 NM_007864 11 B4 2.7↓
1419632_at Tectorin alpha Tecta NM_009347 9 A5.1 3.2↓
1449286_at Netrin G1 Ntng1 NM_030699 3 G1 3.3↓
1425310_a_at Emu2 gene Emid2 BC002218 5 G1 3.6↓
1417234_at Matrix metalloproteinase 11 Mmp11 NM_008606 10 C1 4.0↓
1427056_at Similar to a disintegrin and metalloproteinase with thrombospondin motifs 1
(ADAMTS-1)
Adamts15 AV228731 9 A4 4.3↓
1449979_a_at Sparc/osteonectin, CWCV and kazal-like domains proteoglycan SPOCK 3 NM_023689 8 B3.1 10.4↓
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complete. It is interesting to note that the transcription of
prominent bone matrix genes such as OCN were found to be
down-regulated by homeobox domain proteins such as Msx
[21], and homeobox proteins of the Msx and Dlx families
appear to be potent co-regulators with Runx2 in the control of
BSP gene expression [22]. While our studies failed to reveal
significant differences in expression levels for these Msx and
Dlx homeobox factors, they have identified a drastic down-regulation of Hoxd10, Hoxd11 and Hoxd12 genes in parallel
with a dramatic increase of OCN (Bglap1) and BSP (Ibsp)
expression. It remains to be seen if the Hoxd cluster genes are
indeed involved in the direct, likely negative, regulation of
OCN and/or BSP. Another important factor that is down-
regulated is Gli2, a nuclear transcriptional repressor, which has
a role in the patterning of limb development [23]. This factor
functions in response to sonic hedgehog signaling during
endochondral bone formation [24]. Targeted disruption of the
1037R.V. Sugars et al. / Biochimica et Biophysica Acta 1763 (2006) 1031–1039zinc-finger domain of Gli2 demonstrates the necessity of this
factor for normal endochondral bone development, in that its
absence increased proliferation of immature chondrocytes and
decreased resorption of mineralized cartilage and bone [25].
In skeletal cells, the progression from condensation to overt
differentiation is achieved through pathways of BMP-2,-4,-5
and -7 signaling [26]. BMP-2 and-4 continue to be expressed in
mature bone and may function in skeletal remodeling. Although
no change in gene expression was identified for these BMPs
(BMP2 0.2-fold, Fig. 4) within the microarray data analysis, the
BMP antagonist Noggin (2.5-fold, Fig. 4) was substantially
down-regulated. The Noggin–BMP interaction is important in
the regulation of growth, since Noggin competitively inhibits
the interaction of BMP-2 and -4 with the BMP receptors, types
1A and 1B [27]. The overexpression of Noggin in an animal
model exhibited an osteoporosis phenotype, whereby osteoblast
differentiation and bone formation were inhibited [28]. Thus,
the down-regulation at E19, observed in our analysis is
consistent with the progression of osteogenesis.
Within both the Biological and Cellular GO classifications,
TGF-β1 was highly up-regulated from E15 to E19 (3.8-fold).
TGF-β1 is involved in a vast number of biological processes
and in vitro studies have shown its involvement at every stage of
bone formation, from recruitment of osteoblast progenitors and
the stimulation of their proliferation, to the inhibition of the later
phases of mineralization and bone resorption [29,30]. The
mature TGF-β1 protein is maintained non-covalently associated
with its propeptide (latency-associated peptide (LAP)), which is
the predominant form found in bone. However, this complex
can also combine with the latent transforming growth factor
beta binding protein 1 (Ltbp1) to form a large structure which
ensures correct folding and secretion of the TGF-β1 [31]. This
complex is not widespread within mature mineralized tissues,
and this could offer an explanation for the decrease in Ltbp1
(2.2-fold) at the later time point, which corresponds to the
formation of mineralized tissue [32].
At the second stage of development (E19), a growth plate had
developed, and a primary ossification center and marrow cavity
formed. It was at this stage that the most pronounced changes in
gene expression were witnessed. Whereby, a careful balance
between bone formation by the osteoblasts wasmeasured against
bone resorption by osteoclasts. Within the Biological GO
classification, 18 genes were up-regulated on E19 compared to
E15, and some considerably so, such as Ibsp (BSP, 312.2-fold),
Spp1 (OPN, 190.2-fold) and DMP1 (64.6-fold), all members of
the SIBLING (small integrin binding ligand N-linked glyco-Fig. 4. Analysis of the specific regulation of a number of genes identified from
the gene expression data. Sq-RT-PCR was performed on total RNA isolated
from E15 and E19 mouse metatarsals and these were analyzed on 2% agarose
gels. Lanes: 1—GAPDH, 2—OSX, 3—ACP5, 4—BSP, 5—OSAD, 6—
CHAD, 7—DMP 1, 8—SPOCK 3, 9—MMP 9, 10—MMP 13, 11—TIMP 1,
12—CTS K, 13—NOG, 14—BMP 2.protein) family. Such an extreme increase in expression
highlights the tightly regulated recruitment of osteoblasts into
the remaining cartilage framework and the deposition of a
mineralized bone matrix. Furthermore, there was an increase in
Bglap1 (OCN, 7.8-fold), which is only synthesized in significant
quantities in terminally differentiated osteoblasts [33]. However,
within the Cellular Component GO classifications, a large
number of genes related to bone remodeling predominantly
featured. Of the 50 ECM genes, 40 were up-regulated and
included a number of proteases, MMP 13 (295.4-fold), MMP 9
(36.0-fold), and TIMP 1 (tissue inhibitor of matrix metallprotei-
nases 1, 4.7-fold), and structuralmolecules like the small leucine-
rich proteoglycan family, Fmd (fibromodulin, 10.1-fold), Bgn
(biglycan, 6.9-fold), Aspn (asporin, 5.7-fold) and Dcn (decorin,
5.3-fold). In situ hybridization has localizedMMP 13 to terminal
hypertrophic chondrocytes and to newly recruited osteoblasts
adjacent to TRAP positive cells [34]. In comparison, MMP 9 is
synthesized by preosteoclasts and osteoclasts [35]. These two
MMPs account for the majority of protease activity during
endochondral bone formation, although they are expressed in
non-overlapping cell types at the mineralization front, their
synergistic activity can be observed in mice lacking both MMP
13 and MMP 9 [36]. Phenotypically, these mice had impaired
endochondral bone with limited ECM remodeling, prolonged
chondrocyte survival, delayed angiogenesis and impaired
trabecular bone formation [36]. Linked to this, the activity of
MMP 9 has been shown to be regulated by the Phex gene, a
phosphate-regulating gene with homology to endopeptidases on
the X chromosome [37]. Phex also functions to regulate the
synthesis of various other bone matrix proteins, including BSP
and OCN [37]. At the later time point examined in this study,
Phex was found to have an increased gene expression (4.4-fold),
and therefore potentially contribute to controlling mineralization
and matrix remodeling. In addition, to the increased expression
of MMP 13 and MMP 9, other proteases also showed an
increased expression, including acid phosphatase 5, tartrate
resistant (ACP5) for TRAP (176.2-fold, Supplementary Table 1)
and cathepsin K (28.7-fold, Supplementary Table 1). The
presence of these enzymes demonstrates the full differentiation
and activation of osteoclasts, which was also observed in the
TRAP positive cells at E19 (Fig. 1D). Furthermore, osteoclas-
togenesis is dependent on a number of factors synthesized by
stromal cells, one of which is colony stimulating factor 1 (Csf 1)
[38,39], and Csf 1 was found to be considerably up-regulated in
the current investigation.Only 10ECMproteinswere found to be
down-regulated in the ECM GO classification, and included
MMP11 (4.0-fold) and SPOCK 3 (sparc/osteonectin, cwcv and
kazal-like-domains proteoglycan, 10.4-fold).
The expression of a number of selective genes, with
particular relevance to osteogenesis, was assessed by Sq-RT-
PCR (Fig 4). Many genes, OSX, ACP5, BSP, DMP1, MMP 9,
MMP 13 and cathepsin K showed an up-regulation in gene
expression from E15 to E19 by Sq-RT-PCR (Fig. 4).
Osteoadherin (OSAD) and chondroadherin (CHAD) did not
show any visible difference between the two time points, again
reflecting the gene expression data. SPOCK 3 was found to be
down-regulated in the Sq-RT-PCR, a finding which supports the
1038 R.V. Sugars et al. / Biochimica et Biophysica Acta 1763 (2006) 1031–1039gene profiling data. GAPDH was used for the control
experiments for the Sq-RT-PCR analysis.
The process of mineralization is the least well-defined stage
of skeletal development. Despite a vast amount of information
concerning the molecules involved, information regarding the
biochemical transport processes for the major components of
bone mineral, such as calcium and phosphate, is lacking. It is
thought that mineralization requires cellular transport through a
mechanism based on phosphate secretion to increase the local
concentration [40]. Our gene expression data provide further
evidence for this process, with the significant up-regulation of
the membrane channel protein, termed progressive ankylosis
(Ank 5.3-fold). Ank functions through mechanisms that guide
phosphate to the cell exterior, regulating both intracellular and
extracellular phosphate concentrations [41], via a process that is
mediated by OPN expression [42]. Whereas calcium levels are
regulated by a number of hormones, including parathyroid
hormone (PTH), PTH-receptor protein and 1, 25-dihydroxyvi-
tamin D, and their corresponding receptors, PTH-receptor type I
(Pthr1) and vitamin D receptor (Vdr) respectively. Both
receptors were identified within the Biological GO classification
with an increased gene expression on E19 compared to E15
(Pthr-1 2.5-fold and Vdr 6.3-fold). Vital during the process of
mineralization, the Vdr is a nuclear transcription factor and upon
binding to 1,25-dihydroxyvitamin D, Vdr conformationally
changes. Once activated the Vdr has variable effects that are
dependent on cellular differentiation and the interaction with
other transcription factors. Furthermore in the presence of TGF-
β1, Vdr is up-regulated, which ties in with the microarray data
and the increased expression of TGF-β1 that is observed.
Assessment of gene expression by microarray analysis of any
cells or tissues generates a vast amount of data, and this current
study is no exception. As a result the focus has been limited to
those genes with particular relevance and interest to endochon-
dral ossification. However, when interpreting these data it is
necessary to consider that there are some limitations to this
current set-up. As previously mentioned the whole metatarsal
was examined, which for E15 constituted a relatively homoge-
neous cell population, but by E19 a wide number of more
differentiated cells were present. Furthermore, the perichondri-
um was not removed prior to analysis and this may contribute to
the large number of osteoblastic genes identified.
In summary, this investigation has provided a unique insight
into the complex inter-relationships of gene expression during
endochondral ossification, pre- and post-mineral deposition.
The use of microarray technology has provided a valuable tool
by which to examine this process, and to study genes associated
with biomineralization, and ultimately contribute to the further
understanding of the molecular interactions involved in this
complicated event.
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